Aptevo Therapeutics Statistics
Total Valuation
APVO has a market cap or net worth of $6.69 million. The enterprise value is -$9.59 million.
Important Dates
The next estimated earnings date is Friday, February 20, 2026, before market open.
| Earnings Date | Feb 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
APVO has 997,830 shares outstanding.
| Current Share Class | 997,830 |
| Shares Outstanding | 997,830 |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +448.54% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 4.45% |
| Float | 997,078 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.03, with a Debt / Equity ratio of 0.28.
| Current Ratio | 4.03 |
| Quick Ratio | 3.75 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -242.74% and return on invested capital (ROIC) is -103.86%.
| Return on Equity (ROE) | -242.74% |
| Return on Assets (ROA) | -79.19% |
| Return on Invested Capital (ROIC) | -103.86% |
| Return on Capital Employed (ROCE) | -124.86% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$755,459 |
| Employee Count | 37 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.55% in the last 52 weeks. The beta is 1.48, so APVO's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -99.55% |
| 50-Day Moving Average | 13.96 |
| 200-Day Moving Average | 48.63 |
| Relative Strength Index (RSI) | 29.29 |
| Average Volume (20 Days) | 390,680 |
Short Selling Information
The latest short interest is 219,920, so 22.04% of the outstanding shares have been sold short.
| Short Interest | 219,920 |
| Short Previous Month | 139,996 |
| Short % of Shares Out | 22.04% |
| Short % of Float | 22.06% |
| Short Ratio (days to cover) | 0.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.70M |
| Pretax Income | -26.47M |
| Net Income | -27.95M |
| EBITDA | -26.47M |
| EBIT | -26.70M |
| Earnings Per Share (EPS) | -$351.39 |
Full Income StatementBalance Sheet
The company has $21.06 million in cash and $4.79 million in debt, with a net cash position of $16.27 million or $16.31 per share.
| Cash & Cash Equivalents | 21.06M |
| Total Debt | 4.79M |
| Net Cash | 16.27M |
| Net Cash Per Share | $16.31 |
| Equity (Book Value) | 17.39M |
| Book Value Per Share | 22.67 |
| Working Capital | 17.04M |
Full Balance SheetCash Flow
| Operating Cash Flow | -26.12M |
| Capital Expenditures | n/a |
| Free Cash Flow | -26.12M |
| FCF Per Share | -$26.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
